1. Home
  2. BGSF vs BTAI Comparison

BGSF vs BTAI Comparison

Compare BGSF & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

HOLD

Current Price

$4.40

Market Cap

49.1M

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.87

Market Cap

49.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGSF
BTAI
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.1M
49.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BGSF
BTAI
Price
$4.40
$1.87
Analyst Decision
Strong Buy
Buy
Analyst Count
1
5
Target Price
$9.00
$32.80
AVG Volume (30 Days)
53.9K
578.0K
Earning Date
11-07-2025
11-12-2025
Dividend Yield
44.74%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$263,687,000.00
$752,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.14
$416.40
P/E Ratio
N/A
N/A
Revenue Growth
71.60
N/A
52 Week Low
$2.91
$1.17
52 Week High
$8.22
$9.26

Technical Indicators

Market Signals
Indicator
BGSF
BTAI
Relative Strength Index (RSI) 54.96 43.92
Support Level $4.25 $1.82
Resistance Level $4.50 $2.30
Average True Range (ATR) 0.20 0.17
MACD 0.00 0.01
Stochastic Oscillator 35.92 11.80

Price Performance

Historical Comparison
BGSF
BTAI

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: